John Parkinson

In a small study, the newly FDA approved antifungal demonstrated “clinical activity” against the emerging pathogen.

With millions of Americans affected by sexually transmitted infections (STI) an emphasis on prevention and control strategies was included in the recommendations.

Investigators wanted to study usage of F/TAF vs F/TDF in clinical practice and HIV seroconversion.

Adherence for daily dosing decreased and event-driven PrEP usage increased in a Chinese study.

In a pilot project, customers were surveyed about HIV risk behaviors to gain further insights and assessed for potential PrEP utilization.

A meta-analysis study found that 70% of PrEP users either stopped or had inadequate adherence within 6 months of initiation.

The federal agency gives nod for fexinidazole as the first all-oral treatment for the parasitic illness.

Small survey from gay and bisexual men (GBM) inquired about their experiences during COVID-19 restrictions, and feedback on PrEP.

In Brazil, a concerted effort of recruiting adolescents was made to go out and talk with them about PrEP.

The Pasteur Act in Congress is designed to incentivize pharmaceutical companies to develop new antibiotics.

Investigators surveyed men who have sex with men (MSM) about long-acting injectable pre-exposure prophylaxis (PrEP) including attitudes towards potentially taking it and barriers to usage.

As younger generations come of age, there is a continuous need to inform them about HIV risks, offer insights about prevention strategies, and understand the challenges for people living with HIV (PLWH).

A large study finds 1 out of 2 patients develop at least one during their hospital stay.

A group of personnel at a veterans administration medical center (VAMC)) did a drive-thru to help bolster vaccination amongst coworkers.

Investigators followed patients with pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) for 6 months to review their outcomes.

A Swiss population-based study showed more people in socioeconomically challenged places tested positive more frequently, saw higher hospitalizations, and greater mortality rates than those in higher socioeconomic places.

Azithromycin versus standard care in patients with mild-to-moderate COVID-19, did not reduce the risk of hospital admission or mortality.

The company’s RBX2660, administered as a single dose, demonstrated superiority over standard of care for reducing Clostridioides difficile infection (CDI) recurrence.

CDC says infections linked to the consumption of Jule’s Cashew Brie, a vegan, or plant-based cheese alternative, was linked to the cashews used in the ingredients.

A new Australian study shows the infection rate was 1.61 cases per 1000 people per year over a 3 year study period in participants with access to the therapy.

The therapy would be the first capsid inhibitor and the only HIV treatment option administered every 6 months.

The Food and Drug Administration (FDA) said the company is concerned about cyclospora contamination on the company’s Dole Fresh Blueberries brand.

A study looked at the prevalence of Metallo-B-lactamase (MBLs) producing A. baumannii isolates in one hospital setting.

The newly approved therapy will use the brand name, Brexafemme, and is a one-day, novel, oral treatment for vaginal yeast infection.

Sensors provided data for more hand washing opportunities for healthcare workers and affected related behaviors.

During the pandemic, one regional health system looked at the age distribution of the virus and hospitalization and mortality rates.

With a small number of heart-related adverse effects in younger people, the US Food and Drug Administration (FDA) will move towards a warning statement for Pfizer and Moderna vaccines.

Regeneron’s monoclonal antibodies, casirivimab and imdevimab (REGEN-COV), reduced risk of death by 20% in patients hospitalized with COVID-19 who had not mounted their own immune response.

This mutation also known as B.1.617.2, and first discovered in India is making its way westward and is an emerging infection in the US.

With the company reporting its data today and it applying for authorization with regulatory bodies internationally, and later this year with the US Food and Drug Administration (FDA), what does the prospect of this new vaccine mean to people in the US and internationally?